Melanoma arises from the uncontrolled growth of melanocytes, the pigment-producing cells of the skin, and is strongly linked to ultraviolet radiation exposure, chronic irritation, and friction. Because these tumors invade and spread early, many patients are diagnosed only after distant metastases have taken hold. Yet melanoma carries an unusually high mutational burden, and that burden makes it highly visible to the immune system. It was precisely this immunogenicity that made melanoma the first cancer in which modern immunotherapy was tested, beginning with the approval of interleukin-2 for metastatic disease in 1998. That early success came with a heavy price: interleukin-2’s toxicity was so severe that its use remains confined to a handful of specialized centers.

The true turning point came with immune checkpoint blockade. James Allison’s work on cytotoxic T lymphocyte-associated protein 4, or CTLA-4, produced ipilimumab, an antibody that releases a molecular brake on T cells and slows tumor growth. Subsequent discoveries of programmed cell death protein 1 (PD-1), its ligand PD-L1, T-cell immunoglobulin and mucin domain 3 (TIM3), and lymphocyte activation gene 3 (LAG3) expanded the arsenal. The numbers tell a striking story: objective response rates climbed from roughly 6 to 19 percent with ipilimumab alone, to 21 to 44 percent with the PD-1 inhibitor nivolumab, and to 53 to 61 percent when anti-PD-1 and anti-CTLA4 antibodies were combined in advanced melanoma.

At the heart of these therapies lies the tumor microenvironment, the cellular ecosystem surrounding a tumor, and the review devotes detailed attention to how its inhabitants decide the fate of immunotherapy. Cytotoxic CD8-positive T cells are the primary killers, releasing perforin and granzymes to destroy tumor cells, but their activation depends on helper CD4-positive T cells. The Th1 subset of helper cells supports cytotoxicity and produces the inflammatory signals interferon-gamma and tumor necrosis factor-alpha, which directly kill tumor cells. By contrast, Th2 cells secrete cytokines such as interleukin-4 and interleukin-13 that suppress cytotoxic function, while regulatory T cells inhibit immune activity outright. Memory T cell populations add another layer: in mouse models of metastatic melanoma, circulating memory CD8-positive T cells not only halted lung lesions but also provided durable protection against spread to lymph nodes.

B cells, often overlooked in cancer immunology, are emerging as important players. In melanoma, they gather within tertiary lymphoid structures inside tumors, where they enhance antigen presentation, amplify cytokine signaling, and produce tumor-specific antibodies associated with better outcomes and stronger responses to checkpoint inhibitors. Laboratory studies show that when human B cells are exposed to melanoma secretions, they develop into plasmablast-like cells that release the chemokines CCL3, CCL4 and CCL5, attracting T cells and boosting PD-1-positive T cell activation. Notably, the abundance of these cells in pretreatment tumors can predict how patients will respond to checkpoint blockade.

The innate immune system supplies both allies and saboteurs. Natural killer cells destroy tumor cells directly and recruit other immune players through secreted signals, making them targets for both checkpoint drugs and adoptive transfer strategies. Dendritic cells, the only immune cells capable of activating naive T cells, can be harvested from patients, loaded with tumor antigens in the laboratory, and returned as therapeutic vaccines. Macrophages, meanwhile, display remarkable plasticity: M1-like tumor-associated macrophages fight the tumor, while M2-like subsets promote progression and immune suppression, and a major therapeutic goal is reprogramming them toward the anti-tumor state. Against these allies stand myeloid-derived suppressor cells, whose high frequency in the blood correlates with worse outcomes on checkpoint therapy, and cancer-associated fibroblasts, which sculpt an immunosuppressive environment by releasing factors that dampen T cell and natural killer cell function, often in pathways tied to BRAF mutations.

Biotherapies represent the newest frontier. Adoptive cell therapy transfers living lymphocytes, expanded or gene-edited outside the body, back into patients, and includes tumor-infiltrating lymphocyte therapy, T cell receptor therapy, and chimeric antigen receptor T cells. In a pivotal trial, patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy lived significantly longer without progression than those treated with ipilimumab. Engineered innovations are pushing further: an injectable, photocurable gelatin methacryloyl hydrogel that serves as a local depot for CAR-T cells significantly extended survival in mice compared with conventional delivery, and a 12-patient trial of GD2-specific CAR-T cells found the approach well tolerated with no dose-limiting toxicities. RNA vaccines add another weapon, with the liposomal FixVac vaccine targeting four shared melanoma antigens and driving durable responses in patients with unresectable disease. Oncolytic viruses complete the picture: talimogene laherparepvec, marketed as Imlygic, is injected directly into tumors every two weeks, where it destroys cancer cells and simultaneously provokes a systemic immune attack.

Yet the revolution is incomplete. Up to 60 percent of melanoma patients treated with checkpoint inhibitors experience severe immune-related adverse events, as the same brakes that restrain T cells against tumors also protect healthy organs, and delayed adverse events can be fatal. Resistance is equally troubling: PD-1 antibodies alone produce response rates of only 19 to 45 percent in metastatic melanoma, and roughly a third of initial responders eventually relapse. Mechanisms of resistance include melanoma dedifferentiation, loss of antigen presentation, immune cell exclusion linked to PTEN loss, myeloperoxidase activity, and metabolic rewiring. Promising countermeasures are emerging, among them tilsotolimod, which triggers a localized type 1 interferon response, and inhibitors of the kinase TBK1, which lower the threshold for T cell cytotoxicity and enhance responses to PD-1 blockade in patient-derived models.

The clearest path forward, the review concludes, is rational combination. Pairing nivolumab with ipilimumab produced a median overall survival exceeding 60 months, compared with 36.9 months for nivolumab alone and 19.9 months for ipilimumab alone. The LAG3 inhibitor relatlimab combined with nivolumab, now FDA-approved as first-line therapy for metastatic melanoma, extended progression-free survival to 10.1 months versus 4.6 months with PD-1 blockade alone. Combining immunotherapy with targeted drugs such as the BRAF inhibitor dabrafenib and MEK inhibitor trametinib, with radiotherapy, which can provoke abscopal responses at distant tumor sites, and with agents like guadecitabine that deplete suppressor cells, all show clinical benefit. Neoadjuvant approaches are particularly striking: giving nivolumab and relatlimab before surgery achieved a pathologic complete response rate of 57 percent, and responding patients enjoyed one-year relapse-free survival of 100 percent. The authors argue that the future lies in precision medicine, using biomarkers to match each patient with the right combination, converting immunologically cold tumors into hot ones, and ensuring that the remarkable gains of the immunotherapy era reach every patient rather than a fortunate few.

Subject of Research: Immunotherapy mechanisms and combination strategies in malignant melanoma

Article Title: Insights for the immunotherapy in malignant melanoma: a new revolution

Article References: Xuan, J., Gao, Z., Wei, C., & Gu, J. (2024). Insights for the immunotherapy in malignant melanoma: a new revolution. Clinical Cancer Bulletin, 3(1), Article 21. https://doi.org/10.1007/s44272-024-00026-8

Image Credits: AI Generated

DOI: 10.1007/s44272-024-00026-8

Keywords: melanoma, immunotherapy, immune checkpoint inhibitors, PD-1, CTLA-4, tumor microenvironment, adoptive cell therapy, TIL therapy, RNA vaccines, oncolytic virus, combination therapy, drug resistance

Melanoma, one of the deadliest forms of skin cancer, often remains undetected until it reaches advanced stages where treatment becomes significantly more challenging. Early identification is foundational to improving patient prognosis and survival rates. As the prevalence of skin cancers rises globally, the necessity for efficient diagnostic solutions has never been more urgent. Traditional diagnostic methods heavily rely on the expertise of dermatologists, which can sometimes yield inconsistent results due to subjective interpretations. Thus, the integration of artificial intelligence into this field marks a transformative evolution.

The study leverages dermoscopy images, which are critical in the evaluation of skin lesions. These images provide intricate insights into skin features that are crucial for distinguishing between benign and malignant growths. However, manually analyzing dermoscopy images can be tedious and prone to error, underscoring the need for automated systems that can deliver accurate assessments.

By implementing a hybrid model that amalgamates the strengths of both CNNs and ANNs, the research team addressed the limitations often encountered in stand-alone systems. CNNs excel at extracting high-level features from images, leveraging deep learning architectures to recognize patterns that are not readily visible to the human eye. In contrast, ANNs contribute robust decision-making capabilities that utilize these features to enhance classification performance. The synergistic effect of combining these methodologies results in a powerful tool capable of discerning melanoma with improved precision.

This multifaceted approach begins at the preprocessing stage, where dermoscopy images are meticulously adjusted to ensure uniformity, thus optimizing the input for machine learning algorithms. Subsequent layers of CNN are designed to capture rich and complex features of skin lesions, progressively refining the image data to extract essential characteristics. The outputs from these convolutional layers are then funneled into the ANN, where sophisticated algorithms analyze the extracted features, culminating in a decisive classification of the images as benign or malignant.

In their experiments, the researchers utilized a comprehensive dataset comprising diverse dermoscopy images, ranging from common benign moles to various stages of melanoma. This diversity is crucial as it ensures that the model generalizes well across different skin types and conditions, a common challenge in dermatological diagnostics. The evaluation metrics used in the study reaffirmed the model’s effectiveness, showcasing notable improvements in accuracy, sensitivity, and specificity metrics over existing models.

Moreover, the study underscores the importance of explainability in AI-driven medical solutions. As healthcare professionals increasingly adopt AI tools, it becomes essential that these systems not only produce accurate results but also provide clear reasoning for their classifications. The architecture of the model designed in this study was enhanced to provide visual feedback on the decision-making process, allowing dermatologists to interpret AI findings more effectively and integrate them seamlessly into their clinical practices.

This research adds a significant layer of utility by presenting a robust framework that could potentially be integrated into current clinical systems, paving the way for real-time melanoma detection solutions in dermatology offices and hospitals across the globe. As AI technology evolves, its contributions to healthcare are destined to grow, transforming how medical professionals approach diagnostics and patient care.

The researchers have called for collaboration between technologists and healthcare practitioners to consistently refine these models further, making them even more tailored to specific populations. Cultural and geographical differences can influence the presentation of skin lesions, and thus the training datasets should reflect this diversity for broader applicability.

Additionally, the study opens doors for future explorations into integrating other forms of imaging technologies or data points, such as genetic markers, which could further enhance predictive capabilities. The potential for these AI-driven models to incorporate vast amounts of patient data creates a fertile ground for pioneering research that promises to redefine cancer care methodologies.

As this innovative modality permeates the medical landscape, it also brings important discussions about ethical considerations surrounding the deployment of AI in healthcare. Issues such as data privacy, algorithmic bias, and the need for regulatory frameworks are essential conversations as the technology matures. Ensuring that these systems function equitably and responsibly within society is paramount as we navigate the future of AI and medicine.

The team of Alshmrani, Alotaibi, and Alfakeeh is poised at the forefront of this transformative field, championing a model that not only enhances clinical accuracy but also bridges the gap between AI capabilities and practical applications in medicine. Their contributions underscore an exciting future in which technology and healthcare converge to enhance patient outcomes with unprecedented precision and reliability.

In conclusion, the fusion of multi CNN features with ANN represents an important advancement in the early classification of melanoma using dermoscopy images. By integrating cutting-edge machine learning techniques with rigorous medical analysis, this study not only showcases the potential of artificial intelligence but also highlights a pathway for improved diagnostic practices in dermatology, ultimately aiming to enhance patient care and outcomes in oncology.

Subject of Research: Early classification of melanoma using dermoscopy images through a hybrid model of CNN and ANN

Article Title: Fusion of multi CNN features with ANN for early classification of melanoma using dermoscopy images

Article References:

Alshmrani, A.S., Alotaibi, F.M. & Alfakeeh, A.S. Fusion of multi CNN features with ANN for early classification of melanoma using dermoscopy images.
Discov Sustain (2026). https://doi.org/10.1007/s43621-025-02556-0

Image Credits: AI Generated

DOI: 10.1007/s43621-025-02556-0

Keywords: melanoma, early classification, dermoscopy images, convolutional neural networks, artificial neural networks, machine learning, healthcare innovation, medical imaging, AI in dermatology, skin cancer detection.